University of Hertfordshire

STATISTICAL INPUT INTO CLINICAL TRIALS

Clinical Trials Support Network (CTSN)

Standard Operating Procedure for Statistical Input into Clinical Trials at the University of Hertfordshire

<table>
<thead>
<tr>
<th>SOP Number: gSOP-34-01</th>
<th>Effective Date: 26th April 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Version Number: 1.0</td>
<td>Review Date: 3 years (or as required)</td>
</tr>
</tbody>
</table>

1.0 BACKGROUND

This is a University of Hertfordshire standard operating procedure. University of Hertfordshire (UH) acknowledges West Hertfordshire Hospitals NHS Trust (WHHT) Research & Development (R&D) which has allowed UH to use the SOPs developed by WHHT where possible, modified for local implementation.

This SOP sets out guidance for the statistical aspects of planning, monitoring, analysis and reporting of research studies and clinical trials, to ensure compliance with Good Clinical Practice (GCP) for research projects managed or sponsored by University of Hertfordshire (UH). Where there are potential conflicts between different collaborating organisations’ SOPs, project level working instructions should be developed, to determine precedence.

2.0 PURPOSE

This document defines the University’s procedures for the responsibilities of Statisticians and Chief Investigators (CI) in the development, review and approval of Statistical Analyses Plan (SAP), clinical trial protocols and Case Report Forms (CRF) for research projects managed or sponsored/co-sponsored by UH.

To review statistical principles and considerations in the design, conduct, analysis and reporting of research studies.

To comply with GCP: ‘a standard for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of clinical trials that provides assurance that the data and reported results are credible and accurate, and that the rights, integrity and confidentiality of trial subjects are protected.’

This SOP is specifically for CTIMPs, however in the absence of a documented procedure can be used as guidance for any other clinical study.

Full details of monitoring of study data to ensure its validity is outside the scope of this SOP (see gSOP-12).

3.0 APPLICABLE TO

This document is uncontrolled if printed. Current electronic version of this document should be accessed via the university website.
This applies to all staff involved in clinical research sponsored/co-sponsored by UH, including but not limited to: Chief Investigators, Principal Investigators, Research Fellows, Consultants, Statisticians, Clinical Trial Pharmacists, Research Managers, Research Nurses, Clinical Trial Practitioners, Allied Health Professionals, Trial Coordinators, Clinical Studies Officers, Data Managers, Research Assistants and Students.

4.0 RESPONSIBILITIES

The sponsor, or their delegated representative, is responsible for ensuring the quality of their trial through the use of appropriately qualified Statisticians in the trial design, interim and final analysis.

The Trial Statistician is responsible for:

- Ensuring that the protocol is statistically sound and for providing input into the design of the CRF
- Reviewing and approving all statistical sections before a document (protocol, grant application or manuscript) is submitted for funding, approval or publication
- Ensuring that all data required for the analysis of outcome measures specified in the trial protocol are accurately captured on CRF. Any data that is not strictly necessary for analysis or trial management should not be collected
- Ensuring oversight on all data management (coding and definitions of variables).

5.0 PROCEDURE

Only general principles of statistical procedures are described below. More detailed sources of information are: the Trial Master File for a particular study or the statistical analysis plan (SAP).

5.1 Statistical input into Trial Design

i) All research studies should obtain statistical input at the protocol development stage

ii) For Clinical Trials of an Investigational Medicinal Product (CTIMP), each trial must have its own designated Trial Statistician who must be suitably experienced

iii) For clinical trials, statistical input will involve all of the following:

   a) Initial advice on appropriate trial design and indicative sample size (including potential power of the study)
   b) Formal and on-going input into trial design, conduct, analysis, interpretation and publication
   c) Developing a Statistical Analysis Plan (SAP) in conjunction with the Chief Investigator, project team and any necessary external stakeholders

iv) All CTIMPS will be given the following:

   a) Sample size based on the trials primary outcome
   b) Method of treatment allocation: e.g. randomisation
   c) Summary of statistical analyses for the primary outcome
   d) Approximate timings of any interim analyses, if applicable.

v) The CI and research team are responsible for identifying clinically important primary and secondary outcomes. Input from the statistician should be obtained to ensure the study is
feasible based on sample size calculations, ease of data collection via CRF, and transformations or changes of scale more suitable for analysis

vi) The final SAP should be reviewed and agreed upon between the Statistician and project team members. All SAP versions should be signed and dated by the Statistician and CI, and kept in the Trial Master File

5.2 Randomisation

The method of randomisation will be agreed by the project team.

5.3 Statistical input into Data Collection and Handling

i) The Trial Statistician, in collaboration with the Trial Coordinator or manager, should ensure that the design of the trial's main database permits the efficient extraction of data in a format suitable for use in a statistical package (statistical analysis file)

ii) The Statistical Analysis Plan (SAP) should include a document specifying variables; their named, formats and the overall structure of the data that the Data Manager will provide to the Trial Statistician on database lock

iii) The Trial Statistician in collaboration with the Data Manager should develop programs that can perform extensive range and consistency checks on the variables in the statistical analysis files. This is in addition to any checking that is incorporated within the trial database. These checks should be run prior to each analysis of the study data

iv) Errors that are identified should be detailed in a data queries log so that any amendments can be made to the data set. Case sensitivity analysis may be considered

5.4 Statistical programming

i) A copy of the statistical analysis files, derived datasets and programs used in each interim analysis and the final analysis should be locked and archived at the end of the project preferably in separate folders

ii) Programs should be structured and contain enough detail to allow them to be easily followed by another Statistician. They should also contain a brief header description of what they do

iii) All programmes/files should be adequately labelled to identify the trial for which they are applicable

iv) Clear documentation on statistical analysis file specification procedures should exist for exporting from the trial database

v) Whenever possible, all analyses involving the primary outcome measure should be quality controlled by an appropriately experienced person other than the main Statistician. As a minimum, this will include reviewing the data for internal consistency, and consistency with other reports so as to allow the identification of clear anomalies. As a maximum, this will include a repetition of all analyses for the primary outcome.

5.5 Statistical Analysis Plan (SAP)

i) The SAP is a comprehensive and detailed description of all statistical methods to be used in a trial
ii) The SAP should provide enough detail for a qualified statistician with no previous experience of the trial to perform the final analyses

iii) Some parts of the SAP may change, and be version controlled, to account for unpredictable features of data, or to incorporate new analytical ideas. Any changes between the original protocol and the final SAP must be explained

iv) The SAP must be finalised prior to the data base lock or snapshot for interim analyses

5.6 Interim analysis

i) For interventional and larger observational studies, partial interim analyses are essential for monitoring the progress of a trial and for the regular assessment of data completeness and quality. Interventional studies will periodically consider interim analyses to assess safety and/or efficacy through their Data Monitoring or Trial Steering Committees.

ii) A full interim analysis should only be required if detailed in the study protocol or for safety concerns. This must be requested via the sponsor or data monitoring committee

iii) Interim analyses are considered in detail in the Statistical Analysis Plan

5.7 Statistical Reporting

i) Data should not be released to third parties before the primary publication of the main trial

ii) The SAP should be reviewed periodically

iii) The Statistician should prepare summary reports for the Clinical Trial project team and external stakeholders as required

iv) The Statistician's reports should be used in the writing of trial publications

v) Any table and figures presented within statistical reports and presentation should be obtained directly as an output from programs used to generate them wherever possible. This will ensure that minimal intervention is required to reproduce them

vi) All reports should be checked and endorsed by the Trial Statistician prior to their release

6.0 RELATED DOCUMENTS

- gSOP-14- Writing Research Protocols

7.0 APPENDIX

- Appendix 1 – Definitions

8.0 VERSION HISTORY

Revision Chronology:

This document is uncontrolled if printed. Current electronic version of this document should be accessed via the university website.
9.0 AUTHORSHIP & APPROVAL

Author

Signature          Date

Pro-Vice Chancellor (Research & Enterprise) Approval

Signature          Date
10.0. AGREEMENT

Please detach and retain within your training files

I have read and understood the contents and requirements of this SOP (ref gSOP-034-01) and accept to follow University policies implementing it.

Recipient

Signature: .............................................................Date: .......................  
Name & Position: ...............................................................

Please retain copy of the signed form for your reference in your training file
Appendix 1: Definitions

Chief Investigator (CI)
A Registered Physician, Dentist, Pharmacist or Registered Nurse who has overall responsibility for the conduct of the trial.

Clinical Trial
A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or control) to evaluate the effects of those interventions on health outcomes.

Clinical Trial of Investigational Medicinal Product (CTIMP)
A study that looks at the safety or efficacy of a medicine/food stuff/placebo in humans as defined by the Medicines for Human Use Regulations (2004).

Delegated Individual (DI)
An individual delegated by the PI to carry out their task(s).

Good Clinical Practice (GCP)
As defined in the Regulations.

International Conference on Harmonisation (ICH)
The ICH produced a series of guidelines in 1996, E6 being the guideline on Good Clinical Practice, otherwise known as (ICH-GCP).

Trial Master File
The Trial Master File (TMF) will be held at the principal site by the sponsor, Chief Investigator or at the coordinating Centre. The TMF should contain all essential documents defined as documents which individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced. A Trial Master File should be set up at the beginning of a trial and maintained up-to-date throughout the trial until trial conclusion.

For trials currently running, it is recommended that Section 8 of the ICH-GCP Guideline is followed as guidance in order to meet statutory requirements. However, some of the documents listed may not be available or applicable in many non-commercial trials. The appropriate documentation will vary according to the trial and sponsor requirements.